Argenx Shares Surge on Pipeline Progress and Strategic Moves but Rank 307th in $360M Trading Volume

On September 5, 2025, , ranking 307th in the day’s market activity. The stock’s performance was driven by positive developments in its pipeline and strategic updates.

Recent clinical progress for Vyvgart, argenx’s flagship therapy for myasthenia gravis, highlighted its potential to expand into broader patient populations. , supporting a potential FDA label expansion. Analysts, including those at and RBC, reiterated optimistic ratings, citing the drug’s efficacy across subtypes and its competitive positioning in the autoimmune disorder market.

Leadership changes also contributed to investor sentiment. The appointment of , PhD, as Chief Operating Officer at Hemab Therapeutics, a subsidiary of argenx, signaled strategic reinforcement in operational execution. Additionally, , a novel therapeutic candidate, further underscoring its R&D pipeline’s depth.

Upcoming investor conferences and regulatory milestones, including the filing process for Vyvgart, are expected to maintain momentum. .

To set up this back-test precisely I need to pin down a few implementation details that aren’t fully specified yet:

1. Stock universe • Do we look at all U.S. listed common shares (NYSE + ), or a narrower universe such as the S&P 500, Russell 3000, etc.? • If it’s a custom universe, could you provide (or point to) a ticker list?

2. Entry and exit prices • Should the position be opened at the same-day close and exited at the next-day close (a close-to-close “one-day hold”), or do you prefer open-to-close / close-to-open implementation?

3. Position sizing • Equal weight for each of the 500 names, or volume-weighted / market-cap-weighted? • Any constraints on maximum position size per name or sector?

4. Transaction costs & slippage • Do we assume zero costs, or would you like to include a commission plus a bid-ask spread assumption?

Once these points are clarified I can generate a retrieval plan and run the back-test.